JP2006515870A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006515870A5 JP2006515870A5 JP2006500369A JP2006500369A JP2006515870A5 JP 2006515870 A5 JP2006515870 A5 JP 2006515870A5 JP 2006500369 A JP2006500369 A JP 2006500369A JP 2006500369 A JP2006500369 A JP 2006500369A JP 2006515870 A5 JP2006515870 A5 JP 2006515870A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- ophthalmic
- vaccine
- vaccine according
- neuropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccines Drugs 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 8
- 229920001577 copolymer Polymers 0.000 claims 6
- 210000003169 Central Nervous System Anatomy 0.000 claims 5
- 206010022114 Injury Diseases 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 210000001428 Peripheral Nervous System Anatomy 0.000 claims 4
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 230000000240 adjuvant Effects 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 206010015037 Epilepsy Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000007642 Vitamin B Deficiency Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 201000010874 syndrome Diseases 0.000 claims 2
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 1
- 206010061888 Amaurotic familial idiocy Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000003808 Amyloid Neuropathy Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010002855 Anxiety Diseases 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 206010003882 Axonal neuropathy Diseases 0.000 claims 1
- 208000006373 Bell Palsy Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 206010004659 Biliary cirrhosis Diseases 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 208000003295 Carpal Tunnel Syndrome Diseases 0.000 claims 1
- 201000011470 Charcot-Marie-Tooth disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 201000010450 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000001636 Diabetic Neuropathy Diseases 0.000 claims 1
- 206010012680 Diabetic neuropathy Diseases 0.000 claims 1
- 229940012356 Eye Drops Drugs 0.000 claims 1
- 201000005603 Fabry disease Diseases 0.000 claims 1
- 210000000256 Facial Nerve Anatomy 0.000 claims 1
- 206010017374 Friedreich's ataxia Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 206010019016 Haemorrhagic stroke Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 208000007999 Hyperesthesia Diseases 0.000 claims 1
- 206010020993 Hypoglycaemia Diseases 0.000 claims 1
- 102100016020 IFNG Human genes 0.000 claims 1
- 101700086956 IFNG Proteins 0.000 claims 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 claims 1
- 206010061256 Ischaemic stroke Diseases 0.000 claims 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000008892 Lipoid Proteinosis of Urbach and Wiethe Diseases 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- 206010025476 Malabsorption Diseases 0.000 claims 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229960000282 Metronidazole Drugs 0.000 claims 1
- 208000005264 Motor Neuron Disease Diseases 0.000 claims 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N Nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims 1
- 229960000564 Nitrofurantoin Drugs 0.000 claims 1
- 208000004361 Obstructive Lung Disease Diseases 0.000 claims 1
- 108009000578 Oxidative Stress Proteins 0.000 claims 1
- 102100004920 PEX7 Human genes 0.000 claims 1
- 108060006186 PHYH Proteins 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 claims 1
- 206010034606 Peripheral neuropathy Diseases 0.000 claims 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims 1
- 206010034699 Peroneal muscular atrophy Diseases 0.000 claims 1
- 208000008696 Polycythemia Vera Diseases 0.000 claims 1
- 208000004358 Polyneuropathy Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 206010036181 Porphyria Diseases 0.000 claims 1
- 241000097929 Porphyria Species 0.000 claims 1
- 206010036673 Primary amyloidosis Diseases 0.000 claims 1
- 208000003055 Prion Disease Diseases 0.000 claims 1
- 206010061920 Psychotic disease Diseases 0.000 claims 1
- 208000005587 Refsum Disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 1
- 208000005809 Status Epilepticus Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 208000009056 Telangiectasis Diseases 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 206010050040 VIIth nerve paralysis Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 230000001919 adrenal Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000001977 ataxic Effects 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- ZPUCINDJVBIVPJ-BARDWOONSA-N cocaine Natural products O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000004406 elevated intraocular pressure Effects 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 230000003203 everyday Effects 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 230000002218 hypoglycaemic Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 229960003350 isoniazid Drugs 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 claims 1
- 201000005040 opiate dependence Diseases 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 230000000149 penetrating Effects 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 201000007737 retinal degeneration Diseases 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims 1
- 231100001005 telangiectasia Toxicity 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 108020003112 toxins Proteins 0.000 claims 1
Claims (14)
- コポリマー1、コポリマー1関連ペプチド、及びコポリマー1関連ポリペプチドからなる群から選択される活性薬剤を含む、哺乳動物の治療的免疫のための点眼ワクチン。
- 中枢神経系(CNS)又は末梢神経系(PNS)における損傷、疾患、障害、又は状態によって引き起こされる神経変性を治療するため、CNSにおいて一次損傷に続き得る二次神経変性を予防又は阻害するため、損傷又は疾患、障害又は状態の後でCNS又はPNSにおいて神経再生を促進するため、或いはグルタミン酸毒性からCNS及びPNSの細胞を保護するための、請求項1に記載の点眼ワクチン。
- 前記損傷が脊髄損傷、鈍的外傷、穿通性外傷、脳の直撃若しくは対側衝撃、出血性脳卒中、又は虚血性脳卒中である、請求項2に記載の点眼ワクチン。
- 前記疾患、障害、又は状態が、アルツハイマー病を含む老人性痴呆症、パーキンソン病を含むパーキンソン症候群、顔面神経麻痺(ベル麻痺)、ハンティングトン舞踏病、筋萎縮性側索硬化症を含む運動ニューロン疾患、クロイツフェルト−ヤーコブ病を含むプリオン病、アルパーズ病、バッテン病、コケーン症候群、レヴィー小体病、てんかん重積持続状態、手根管症候群、椎間板ヘルニア、ビタミンB欠乏などのビタミン欠乏、てんかんなどの発作障害、精神分裂病及び不安などの精神病性障害、記憶喪失、痛覚過敏、酸化的ストレス、アヘン耐性及びアヘン依存性、自己免疫疾患、アミロイド多発性神経障害、糖尿病性神経障害、尿毒症性神経障害、ポルフィリン症性多発性神経障害などの疾患に関連する末梢性神経障害、低血糖症、シェーグレン−ラルソン症候群、急性感覚性神経障害、慢性運動失調性神経障害、胆汁性肝硬変、原発性アミロイドーシス、閉塞性肺疾患、先端巨大症、吸収不良症候群、真性赤血球増加症、IgAガンマパシー及びIgGガンマパシー、ニトロフラントイン、メトロニダゾール、イソニアジドなどの種々の薬物及びアルコール又は有機リン酸などの毒素の合併症、シャルコー−マリー−ツース病、毛細血管拡張性運動失調、フリートライヒ運動失調、副腎脊髄神経障害、巨大軸索神経障害、レフサム病、ファブリー病、リポタンパク質症、非動脈炎性眼神経障害、年齢関連黄斑変性、網膜変性などの網膜障害、又は緑内障などの異常上昇した眼圧と関連する疾患である、請求項2に記載の点眼ワクチン。
- 前記自己免疫疾患が多発性硬化症である、請求項4に記載の点眼ワクチン。
- 前記ワクチンがアジュバントを伴わない活性薬剤を含む、請求項1に記載の点眼ワクチン。
- 前記ワクチンが可溶性アジュバントを伴う活性薬剤を含む、請求項1に記載の点眼ワクチン。
- 前記可溶性アジュバントがサイトカインである、請求項7に記載の点眼ワクチン。
- 前記サイトカインがIL−2、IL−12、IFN−γ、又はGM−CSFである、請求項8に記載の点眼ワクチン。
- 前記活性薬剤がコポリマー1である、請求項1から9までのいずれか一項に記載の点眼ワクチン。
- 前記活性薬剤がコポリマー1関連ペプチド又はコポリマー1関連ポリペプチドである、請求項1から9までのいずれか一項に記載の点眼ワクチン。
- 多発性硬化症患者に毎日又は隔日の頻度で少なくとも1回投与するための、請求項1に記載の点眼ワクチン。
- 7日に少なくとも1回、毎月少なくとも1回まで、2カ月から3カ月に少なくとも1回までの頻度で、非多発性硬化症患者へ定期的に投与するための、請求項1に記載の点眼ワクチン。
- 緑内障患者への投与のための、請求項13に記載の点眼ワクチン。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43831003P | 2003-01-07 | 2003-01-07 | |
US60/438,310 | 2003-01-07 | ||
PCT/IL2004/000006 WO2004060265A2 (en) | 2003-01-07 | 2004-01-06 | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006515870A JP2006515870A (ja) | 2006-06-08 |
JP2006515870A5 true JP2006515870A5 (ja) | 2007-03-01 |
JP5291878B2 JP5291878B2 (ja) | 2013-09-18 |
Family
ID=32713312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006500369A Expired - Fee Related JP5291878B2 (ja) | 2003-01-07 | 2004-01-06 | 治療的免疫のためのコポリマー1を含む点眼ワクチン |
Country Status (12)
Country | Link |
---|---|
US (2) | US20070248569A1 (ja) |
EP (1) | EP1583506B1 (ja) |
JP (1) | JP5291878B2 (ja) |
CN (2) | CN1758922A (ja) |
AT (1) | ATE548045T1 (ja) |
AU (1) | AU2004203772B2 (ja) |
CA (1) | CA2512735C (ja) |
ES (1) | ES2386435T3 (ja) |
HK (1) | HK1084034A1 (ja) |
IL (1) | IL169552A (ja) |
MX (1) | MXPA05007329A (ja) |
WO (1) | WO2004060265A2 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9089509B2 (en) * | 2006-06-28 | 2015-07-28 | Yeda Research And Development Co., Ltd. | Method of treatment of age-related macular degeneration |
EP2195008A1 (en) | 2007-09-24 | 2010-06-16 | Hadasit Medical Research Services & Development Ltd. | Use of copolymer 1 for treatment of muscular dystrophy |
US8697046B2 (en) | 2008-08-15 | 2014-04-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of administering interferon gamma to absorb fluid from the subretinal space |
NZ599899A (en) | 2009-11-10 | 2014-10-31 | Allegro Pharmaceuticals Inc | Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites |
US11673914B2 (en) | 2009-11-10 | 2023-06-13 | Allegro Pharmaceuticals, LLC | Peptide therapies for reduction of macular thickening |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
NZ609938A (en) | 2010-10-11 | 2015-11-27 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
EP2699317B1 (en) | 2011-04-21 | 2016-08-10 | Mapi Pharma Limited | Random pentapolymer for treatment of autoimmune diseases |
US8815511B2 (en) | 2011-10-10 | 2014-08-26 | Teva Pharmaceutical Industries, Ltd. | Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate |
US9611314B2 (en) | 2013-09-13 | 2017-04-04 | The Penn State Research Foundation | Functional peptide analogs of PEDF |
CN106491614A (zh) * | 2016-12-06 | 2017-03-15 | 郑州郑先医药科技有限公司 | 一种用于治疗脊髓损伤的西药组合及用途 |
WO2018136669A2 (en) * | 2017-01-19 | 2018-07-26 | Allegro Phamaceuticals, Inc. | Therapeutic and neuroprotective peptides |
EP3600553A4 (en) | 2017-03-26 | 2020-09-02 | Mapi Pharma Ltd. | GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS |
WO2019173361A2 (en) * | 2018-03-05 | 2019-09-12 | The Schepens Eye Research Institute, Inc. | A therapy for glaucoma and optic neuropathy by targeting colony stimulating factors |
WO2021222913A1 (en) * | 2020-04-30 | 2021-11-04 | Koziol Jeffrey E | Micro dosing of viral vaccines |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4525589A (en) | 1988-10-27 | 1990-05-14 | Regents Of The University Of Minnesota | Liposome immunoadjuvants containing il-2 |
IL104382A0 (en) | 1992-01-17 | 1993-05-13 | Solvay Animal Health Inc | Vaccine containing acemannan as an adjuvant |
US5571515A (en) * | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
US6153182A (en) * | 1997-12-19 | 2000-11-28 | Uab Research Foundation | Lymphotactin as an adjuvant |
CA2320044A1 (en) * | 1998-02-13 | 1999-08-19 | Ruth Maron | Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines |
US6616925B1 (en) * | 1998-04-02 | 2003-09-09 | I.D.M. Immuno-Designed Molecules | Combined preparation for the treatment of neoplasic diseases or of infectious diseases |
JP2003517452A (ja) * | 1999-02-05 | 2003-05-27 | アルク−アベル・アー/エス | 新規粘膜デリバリーシステム |
CA2382652A1 (en) * | 1999-08-24 | 2001-03-01 | Teva Pharmaceutical Industries, Ltd. | A vaccine composition and method of using the same |
WO2001052878A2 (en) * | 2000-01-20 | 2001-07-26 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
US20020037848A1 (en) | 2000-06-07 | 2002-03-28 | Michal Eisenbach-Schwartz | Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
SI1429800T1 (sl) * | 2001-12-06 | 2009-08-31 | Yeda Res & Dev | Cepivo in njegova uporaba za zdravljenje amiotrofiäśne lateralne skleroze |
WO2005030955A1 (ja) * | 2003-09-29 | 2005-04-07 | Chugai Seiyaku Kabushiki Kaisha | Nk細胞に発現するタンパク質 |
JP4501562B2 (ja) | 2004-07-09 | 2010-07-14 | 旭硝子株式会社 | 積層膜付き基材およびその製造方法 |
-
2004
- 2004-01-06 CN CNA2004800062290A patent/CN1758922A/zh active Pending
- 2004-01-06 EP EP04700289A patent/EP1583506B1/en not_active Expired - Lifetime
- 2004-01-06 CA CA2512735A patent/CA2512735C/en not_active Expired - Fee Related
- 2004-01-06 WO PCT/IL2004/000006 patent/WO2004060265A2/en active Application Filing
- 2004-01-06 AT AT04700289T patent/ATE548045T1/de active
- 2004-01-06 MX MXPA05007329A patent/MXPA05007329A/es active IP Right Grant
- 2004-01-06 US US10/541,492 patent/US20070248569A1/en not_active Abandoned
- 2004-01-06 ES ES04700289T patent/ES2386435T3/es not_active Expired - Lifetime
- 2004-01-06 CN CN201110438909.1A patent/CN102580069B/zh not_active Expired - Fee Related
- 2004-01-06 AU AU2004203772A patent/AU2004203772B2/en not_active Ceased
- 2004-01-06 JP JP2006500369A patent/JP5291878B2/ja not_active Expired - Fee Related
-
2005
- 2005-07-06 IL IL169552A patent/IL169552A/en active IP Right Grant
-
2006
- 2006-04-11 HK HK06104409.1A patent/HK1084034A1/xx not_active IP Right Cessation
-
2009
- 2009-05-07 US US12/437,167 patent/US8895501B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006515870A5 (ja) | ||
IL169552A (en) | An eye-drop-containing vaccine containing Copolymer 1 for systemic protection of the nervous system | |
JP2005502616A5 (ja) | ||
CA2451521A1 (en) | Use of poly-glu, tyr for neuroprotective therapy | |
Hohlfeld et al. | The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis | |
Loher et al. | Deep brain stimulation for dystonia: outcome at long-term follow-up | |
JP2008521796A5 (ja) | ||
CA2806942A1 (en) | Compounds for the treatment/prevention of ocular inflammatory diseases | |
JP2004507460A5 (ja) | ||
JP2003532618A5 (ja) | ||
Gedde et al. | Update on aqueous shunts | |
CN110678193A (zh) | 治疗和神经保护肽 | |
CN111760016A (zh) | 卡泊芬净在制备神经保护药物中的应用 | |
JP2002535334A5 (ja) | ||
Bito | Presbyopia | |
Park et al. | Intravitreal bevacizumab and subsequent trabeculectomy with mitomycin c for neovascular glaucoma with previous sutureless vitrectomy | |
US20080044473A1 (en) | Methods of reducing nervous system glial scar formation using cyclosporine components | |
RU2801488C1 (ru) | Способ лечения дефектов роговицы с замедленной эпителизацией с помощью склеральных контактных линз | |
Duan et al. | IL-18 deficiency inhibits both Th1 and Th2 cytokine production but not the clinical symptoms in experimental autoimmune neuritis | |
CN111760015A (zh) | 米卡芬净在制备神经保护药物中的应用 | |
Goodman et al. | Lamellar Keratectomy and Repeat Epikeratoplasty Following Failed Epikeratoplasty | |
Shuaib et al. | Predictive value of intraocular lens power calculation formulae in children | |
Deep et al. | Comparison of the efficacy and safety of bepotastine besilate 1.5% and loteprednol etabonate 0.5% ophthalmic solution in patients of vernal keratoconjunctivitis | |
Hamdi | The Copeland intraocular lens: five to ten years later | |
Shoshany et al. | Anomalous superior oblique muscle in congenital fibrosis of the extraocular muscles |